Cargando…

Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer

OBJECTIVE: This study aimed to evaluate the efficacy and safety profile of capecitabine and oxaliplatin (CAPOX) and 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimens as adjuvant treatment in patients with stage III colon cancer. METHODS: A total of 243 patients who received CAPOX and FOL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Degirmencioglu, Serkan, Tanrıverdi, Ozgur, Demiray, Atike Gokcen, Senol, Hande, Dogu, Gamze Gokoz, Yaren, Arzu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Clinical Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567718/ https://www.ncbi.nlm.nih.gov/pubmed/31099282 http://dx.doi.org/10.1177/0300060519848258

Ejemplares similares

Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer
por: Gökçen Demiray, Atike, et al.
Publicado: (2022)

Effects of Serum Leptin and Resistin Levels on Cancer Cachexia in Patients With Advanced-Stage Non–Small Cell Lung Cancer
por: Demiray, Gökcen, et al.
Publicado: (2017)

The Effect of Continuing Chemotherapy after Chemoradiotherapy during the Time to Surgery on Tumor Response and Survival for Local Advanced Rectal Cancer
por: Demiray, Atike Gökçen, et al.
Publicado: (2022)

Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines
por: Yaylali, Yalin Tolga, et al.
Publicado: (2016)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Postoperative Adjuvant Chemotherapy Regimen of CAPOX Combined With Ninjin'yoeito in an Elderly Patient With Stage III Colon Cancer: A Case Report
por: Aomatsu, Naoki, et al.
Publicado: (2020)

Evaluation of hypermetabolic mediastinal-hilar lymph nodes determined by PET/CT with EBUS-TBNA and calculation of SUVmax cutoff values in differentiation of malignancy
por: Ugurlu, Erhan, et al.
Publicado: (2023)

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
por: Pectasides, Dimitrios, et al.
Publicado: (2015)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
por: Tsai, Yi-Jian, et al.
Publicado: (2016)

POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial
por: Su, Liyu, et al.
Publicado: (2022)

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
por: Snoeren, Nikol, et al.
Publicado: (2010)

Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study
por: Osawa, Hiroshi, et al.
Publicado: (2015)

Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection
por: Xu, Ju Ling, et al.
Publicado: (2019)

Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis
por: Felismino, Tiago Cordeiro, et al.
Publicado: (2020)

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study()()
por: Snoeren, Nikol, et al.
Publicado: (2017)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
por: Zhou, Meijiao, et al.
Publicado: (2022)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study
por: Murono, Koji, et al.
Publicado: (2023)

Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II)
por: Hattori, Norifumi, et al.
Publicado: (2019)

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy
por: Han, Song-Hee, et al.
Publicado: (2019)

The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients
por: Zhou, Juan, et al.
Publicado: (2016)

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
por: Murray, Nigel P, et al.
Publicado: (2019)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
por: Lou, Yun-Ting, et al.
Publicado: (2015)

KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
por: Vauthey, J-N, et al.
Publicado: (2012)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
por: Park, Hye Eun, et al.
Publicado: (2021)

Adjuvant Chemotherapy after Neoadjuvant Chemotherapy and Long-term Outcomes of CAPOX Plus Bevacizumab Followed by TME for High-risk Localized Rectal Cancer
por: Nishimura, Junichi, et al.
Publicado: (2020)

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)

Changes in Body Composition during Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer
por: Chung, Eric, et al.
Publicado: (2019)

Isolated Femoral Muscle and Bone Metastases Rarely Encountered in Testicular Seminoma
por: Degirmencioglu, Serkan, et al.
Publicado: (2013)

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer
por: Huang, Wen-Yen, et al.
Publicado: (2017)

Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary
por: Yoshino, T, et al.
Publicado: (2012)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study
por: Li, Shao-Hua, et al.
Publicado: (2023)

A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
por: Okuno, Keisuke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_up398ukscqk3h8i4vv05jfpst5